Drug firm Venus Remedies today said it has received patent grants for its antibiotic drug Sulbactomax from Russian and Ukrainian authorities.
The patent has been granted by Federal Service on Intellectual Property, Patents and Trademarks, Russia and State Enterprise Ukrainian Institute of Industrial Property, Ukraine, Venus Remedies said in a filing to the Bombay Stock Exchange (BSE).
With this patent grant the company can now enter the $780 million anti-biotic market in Russia and also strengthen its presence in Ukrainian market, it added.
Sulbactomax is used in treating bacterial infections, including respiratory tract and urinary tract infections.
The world antibiotic market is presently estimated to be around $37.14 billion and is expected to be $55.18 billion by 2013, it said.
Shares of Venus Remedies were today trading at Rs 268.50 on the BSE in the afternoon trade, up 2.74 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app